Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Insulin regulates astrocyte gliotransmission and modulates behavior
Weikang Cai, … , Emmanuel N. Pothos, C. Ronald Kahn
Weikang Cai, … , Emmanuel N. Pothos, C. Ronald Kahn
Published April 17, 2018
Citation Information: J Clin Invest. 2018;128(7):2914-2926. https://doi.org/10.1172/JCI99366.
View: Text | PDF
Research Article Metabolism Neuroscience

Insulin regulates astrocyte gliotransmission and modulates behavior

  • Text
  • PDF
Abstract

Complications of diabetes affect tissues throughout the body, including the central nervous system. Epidemiological studies show that diabetic patients have an increased risk of depression, anxiety, age-related cognitive decline, and Alzheimer’s disease. Mice lacking insulin receptor (IR) in the brain or on hypothalamic neurons display an array of metabolic abnormalities; however, the role of insulin action on astrocytes and neurobehaviors remains less well studied. Here, we demonstrate that astrocytes are a direct insulin target in the brain and that knockout of IR on astrocytes causes increased anxiety- and depressive-like behaviors in mice. This can be reproduced in part by deletion of IR on astrocytes in the nucleus accumbens. At a molecular level, loss of insulin signaling in astrocytes impaired tyrosine phosphorylation of Munc18c. This led to decreased exocytosis of ATP from astrocytes, resulting in decreased purinergic signaling on dopaminergic neurons. These reductions contributed to decreased dopamine release from brain slices. Central administration of ATP analogs could reverse depressive-like behaviors in mice with astrocyte IR knockout. Thus, astrocytic insulin signaling plays an important role in dopaminergic signaling, providing a potential mechanism by which astrocytic insulin action may contribute to increased rates of depression in people with diabetes, obesity, and other insulin-resistant states.

Authors

Weikang Cai, Chang Xue, Masaji Sakaguchi, Masahiro Konishi, Alireza Shirazian, Heather A. Ferris, Mengyao E. Li, Ruichao Yu, Andre Kleinridders, Emmanuel N. Pothos, C. Ronald Kahn

×

Figure 1

Loss of IR in astrocytes increases anxiety- and depressive-like behavior.

Options: View larger image (or click on image) Download as PowerPoint
Loss of IR in astrocytes increases anxiety- and depressive-like behavior...
(A) mRNA levels of IR and IGF1R from FACS-sorted astrocytes from GIRKO GFAP-GFP reporter (GIRKO/GFP, n = 4) and control GFAP-GFP reporter (IRfl/fl/GFP, n = 3) mice normalized to TBP. **P < 0.01, 2-tailed Student’s t test. (B) Representative FACS profiles of cells from brains of IRfl/fl/GFP and GIRKO/GFP mice. x axis: GFP; y axis: side-scattered light. (C) Glucose tolerance tests on overnight-fasted 3-month-old male IRfl/fl (n = 7) and GIRKO (n = 6) mice following i.p. glucose (2 g/kg). Right: Area under the curve. *P < 0.05, 2-tailed Student’s t test. (D) Representative movement by IRfl/fl and GIRKO mice in the open field. (E) Center zone entries of 4-month-old and 1-year-old female IRfl/fl and GIRKO mice in the open field test. *P < 0.05, ***P < 0.001, 2-tailed Student’s t test; 4-month-old: IRfl/fl, n = 13; GIRKO, n = 11; 1-year-old: n = 6. (F) Latency to feeding of 4-month-old female mice in novelty-suppressed feeding test. *P < 0.05, 2-tailed Student’s t test, n = 12. (G) Sucrose preference of 4-month-old female IRfl/fl (n = 9) and GIRKO (n = 19) mice. *P < 0.05, 2-tailed Student’s t test. (H) Immobility time of 4-month-old female IRfl/fl and GIRKO mice in forced swimming test following saline or 16 mg/kg imipramine i.p. 1 hour before testing. *P < 0.05, 2-way ANOVA followed by Tukey’s multiple comparisons, IRfl/fl, n = 11; GIRKO + saline, n = 10; GIRKO + imipramine, n = 12. (I) Immobility time of 1-year-old female IRfl/fl and GIRKO mice in forced swimming test. **P < 0.01, 2-tailed Student’s t test, n = 6. (J) Serum corticosterone of 6-month-old female IRfl/fl and GIRKO mice before and after 5 minutes of restraint. **P < 0.01, ***P < 0.001, 2-tailed Student’s t test, n = 6. All data are mean ± SEM.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts